Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olinciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 known ✓ | O75343 | 20/20 | 0.69 |
| ▸ | GUCY1A2 known ✓ | P33402 | 20/20 | 0.69 |
| ▸ | GUCY1A1 known ✓ | Q02108 | 20/20 | 0.69 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 20/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olinciguat SCHEMBL16081941 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Olinciguat SCHEMBL16081945 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Olinciguat SCHEMBL29382293 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082087 | 0.94 | GUCY1B2 (0.60) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17611686 | 0.93 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16081910 | 0.93 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL26866727 | 0.92 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL25966687 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18854998 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082433 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | claimed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | claimed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | claimed |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| EP-4570797-A2 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12247025-B2 | Processes for preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240391911-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240368185-A1 | MACROCYCLIC AZOLOPYRIDINES | FULCRUM THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2015106268-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | GUCY1B2 3993/4885GUCY1A2 4105/4885GUCY1A1 3797/4885 |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | GUCY1B2 8/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-12247025-B2 | Processes for preparation of soluble guanylate cyclase stimulators | GUCY1B1, GUCY1B2, GUCY1A2 | GUCY1B2 2/4885GUCY1A2 3/4885GUCY1A1 4/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | GUCY1B2 3993/4885GUCY1A2 4105/4885GUCY1A1 3797/4885 |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20240368185-A1 | MACROCYCLIC AZOLOPYRIDINES | FLNA, AFF4, FES | GUCY1B2 1269/4885GUCY1A2 937/4885GUCY1A1 1336/4885 |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | GUCY1B2 4096/4885GUCY1A2 4190/4885GUCY1A1 3899/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20240391911-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.